• Home
  • About Us
  • Science
    • Vaccines
    • Antibodies
  • Our Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Publications
  • Contact Us
    • Find a trial
    • Become an Investigator

Citrullinated glucose-regulated protein 78 is a candidate target for melanoma immunotherapy

by admin | Dec 9, 2022 | Moditope, Vaccines

Victoria Anne Brentville, Peter Symonds, JiaXin Chua, Anne Skinner, Ian Daniels, Katherine Wendy Cook, Sasa Koncarevic, Roxana Martinez-Pinna, Sabaria Shah, Ruhul Hasan Choudhury, Poonam Vaghela, Daisy Weston, Abdullah Al-Omari, James Davis and Lindy G. Durrant...

Result of Annual General Meeting

by admin | Nov 23, 2022 | Latest News, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

14th Annual Meeting of the Protein & Antibody Engineering Summit (PEGS), 14-16 November 2022 in Barcelona, Spain

by admin | Nov 16, 2022 | Antibodies, Avidimab

Bubacarr G Kaira, Foram Dave, Elena Dubinina, Omar Mohammed, Bryony Heath, Poonam Vaghela, Ruhul Choudhury, Tina Parsons, Samantha Paston and Mireille Vankemmelbeke and Lindy G. Durrant

Scancell in-licenses Vaccitech technology to advance Modi-2 towards the clinic

by admin | Nov 7, 2022 | Latest News, Modi-2, Moditope, Regulatory News

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!

37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), 8-12 November 2022 in Boston, MA, USA

by admin | Nov 6, 2022 | Moditope, Vaccines

V Brentville, P Symonds, J Chua, A Skinner, I Daniels, K Cook, S Koncarevic, R Martinez-Pinna, S Shah, RH Choudhury, P Bilimoria1, D Weston, A Al-Omari, J Davis and L Durrant
« Older Entries

Recent Posts

  • Clinical & Corporate Update: Active Immunotherapy for a Cancer-Free Future
  • Scancell initiates new arm (Cohort 4) in SCOPE Phase 2 study to evaluate intradermal administration and an accelerated dosing regimen for iSCIB1+
  • Q&A with Scancell CMO Nermeen Varawalla
  • Director Dealing
  • AACR (American Association for Cancer Research) Annual Meeting, April 2025, Chicago, Illinois

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

About Us
Leadership Team
Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

VACCINES

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2025 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy